Journal
CLINICS IN CHEST MEDICINE
Volume 33, Issue 3, Pages 531-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccm.2012.05.004
Keywords
Eosinophilic asthma; Corticosteroids; Inflammation; Mast cells; Asthma phenotypes
Categories
Funding
- federal grant PAI [P7/30]
- National Institute for Health Research [NF-SI-0611-10148] Funding Source: researchfish
Ask authors/readers for more resources
Inhaled corticosteroids (ICS) have led to improved asthma control and reduced asthma mortality in the Western world. ICS are effective in combating T-helper type 2 driven inflammation featuring mast cell and eosinophilic airway infiltration. Their effect on innate immunity-driven neutrophilic inflammation is poor and their ability to prevent airway remodeling and accelerated lung decline is controversial. Although ICS remain pivotal drugs in asthma management, research is needed to find drugs complementary to the combination ICS/long-acting beta 2-agonist in refractory asthma and perhaps a new class of drugs as a first-line treatment in mild to moderate noneosinophilic asthma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available